

Efficacy of mouth-rinses in reducing SARS CoV-2 viral load in the saliva of COVID-19 positive patients in Indonesia

Submission date 12/04/2021	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/04/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/05/2021	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The purpose of this study is to evaluate the efficacy of commonly used commercial mouth-rinses (Betadine Gargle and Mouthwash, Oxyfresh Pro Formula mouthwash, Pepsodent Active Defense mouthwash) to reduce SARS CoV-2 viral level in the saliva of COVID-19 positive patients. This study will provide evidence on the use of mouth rinses in reducing the viral load in the saliva of the COVID-19 patients and thereby help in reducing transmission of COVID-19.

Who can participate?

Subjects with laboratory-confirmed diagnosis of COVID-19 can participate in the study.

What does the study involve?

Subjects are randomised to receive either Betadine Gargle and Mouthwash, Oxyfresh Pro Formula mouthwash, Pepsodent Active Defense mouthwash or water (control group). They are asked to provide saliva samples by spitting method. Then, subjects are asked to rinse their mouth with mouth-rinse or water. The saliva sample is collected again at 5 min, 3 h and 6 h post-application of mouth-rinse.

What are the possible benefits and risks of participating?

There is no known benefit to the subject from participation in this study. However, their participation may add to the medical knowledge about the efficacy of mouthwashes against SARS-CoV 2, as well as the use of mouthwashes to reduce the spread of COVID-19 through saliva. There is no potential risk to participants from saliva collection methods as it is a non-invasive method.

Where is the study run from?

The study is run from YARSI Hospital (Internal Medicine Department Clinic) (Indonesia)

When is the study starting and how long is it expected to run for?

March 2021 to October 2021

Who is funding the study?
Faculty of Dentistry Trisakti University (Indonesia)

Who is the main contact?
Dr. drg. Armelia Sari Widyarman, armeliasari@trisakti.ac.id

Contact information

Type(s)
Scientific

Contact name
Dr Armelia Sari Widyarman

ORCID ID
<https://orcid.org/0000-0003-1435-2392>

Contact details
Faculty of Dentistry
Trisakti University
Jl. Kyai Tapa No.1
RT.5 / RW.9
Tomang
Grogol Petamburan
West Jakarta City
Special Capital Region of Jakarta
Jakarta
Indonesia
11440
+62 (0)811929379
armeliasari@trisakti.ac.id

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

ClinicalTrials.gov (NCT)
Nil known

Protocol serial number
2021

Study information

Scientific Title
Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: a randomized control trial in Indonesia

Study objectives

PVI-I, CPC, and NaClO₂-based mouth rinses are effective against reducing SARS-CoV-2 viral load in the saliva compared to a control water rinse and the effect will last for 6 hours.

Objectives:

1. To comparatively evaluate the viral load of SARS-CoV-2 in saliva pre- and post-5-minute application of PVP-I, CPC and NaClO₂-based mouth-rinses in COVID-19 positive patients.
2. To assess the duration of efficacy of PVP-I, CPC and NaClO₂-based mouth-rinses in reducing SARS-CoV-2 load in COVID-19 positive patients by the collection of saliva at 3 h and 6 h post-application of mouth-rinses.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 25/03/2021, Institutional Review Board of Faculty of Dentistry, Trisakti University (Jl. Kyai Tapa No.1, RT.5 / RW.9, Tomang, Grogol Petamburan, West Jakarta City, Special Capital Region of Jakarta 11440, Jakarta, Indonesia; +628161908945; komisetikfkg@trisakti.ac.id), ref: 001/Dosen/KEPK/FKG/03/2021

Study design

Single-center single blind interventional randomized clinical trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Reducing the transmission of SARS CoV-2 virus in saliva of COVID-19 patients in Indonesia.

Interventions

The enrolled patients are randomized using Robust Randomization App (RRApp) using a block randomization technique and are allocated to four groups accordingly— PI, NaClO₂, CPC and water control group.

Prior to saliva collection, patients are asked to refrain from eating, drinking, or performing oral hygiene procedures for at least 30 min. Three milliliters of saliva is collected by the passive drool technique from all the enrolled COVID-19 patients at four time points.

Firstly, a baseline saliva sample is collected prior to the intervention of the mouth-rinse. Immediately after this, patients are requested to rinse their mouth with the allocated mouth-rinse for 30 seconds.

Commercial mouth-rinses are prepared at the dilution and dosage recommended by respective manufacturers. In brief, in the PI group 5 ml of PI mouthwash (commercially available as Betadine Gargle and Mouthwash 1%) diluted with 5 ml of water (0.5%) is used whereas in NaClO₂ group, 15 ml of undiluted NaClO₂ mouthwash (commercially available as Oxyfresh Pro Formula) is used. In the CPC group and water control groups, 20 ml of CPC (commercially available as Pepsodent Active Defense mouthwash) and 15 ml sterile water is used, respectively. Three milliliters of saliva is collected again from all subjects five minutes after the use of mouth-

rinse. In order to evaluate the duration of the efficacy of mouth-rinses, salivary samples are collected at the 3 h and 6 h post-rinsing.

Intervention Type

Supplement

Primary outcome(s)

Salivary CT values of SARS CoV-2 is measured using reverse-transcription polymerase chain reaction (RT-PCR) at baseline, 5 min, 3 hours and 6 hours

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

20/10/2021

Eligibility

Key inclusion criteria

Laboratory-confirmed COVID-19 positive patients

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. History of allergy to PI, NaClO₂, CPC and its relevant excipients
2. All forms of thyroid disease or current radioactive iodine treatment
3. Lithium therapy
4. Known pregnancy
5. Renal failure

Date of first enrolment

10/05/2021

Date of final enrolment

10/06/2021

Locations

Countries of recruitment

Indonesia

Study participating centre
Internal Medicine Department Clinic YARSI Hospital
Jl. Letjend Suprpto No.Kav 13
RT.10/RW.5
Cempaka Putih Timur
Cempaka Putih District
Central Jakarta City
Special Capital Region of Jakarta
Jakarta
Indonesia
10510

Sponsor information

Organisation
Trisakti University

ROR
<https://ror.org/019fnr381>

Funder(s)

Funder type
University/education

Funder Name
Universitas Trisakti

Alternative Name(s)
Trisakti University

Funding Body Type
Private sector organisation

Funding Body Subtype
Universities (academic only)

Location
Indonesia

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to confidentiality.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			04/05/2021	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes